Steve N. Slilaty
Chairman, President & CEODr. Steve N. Slilaty, Ph.D. is CEO & Chairman of Sunshine Biopharma, Inc. from October 15, 2009 and serves as its President. Dr. Slilaty joined the Sunshine Biopharma, Inc. on October 15, 2009. He serves as the President, Chief Executive Officer and Chief Scientific Officer of Advanomics Corporation since February 2002. He founded Qbiogene Inc. in 1991 and Genomics One Corporation in 1995. He served as Scientific Director at ALERT B&C Corporation. He was a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada. Dr. Slilaty served as a Consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997. He served as the Chairman of the Scientific Advisory Board at Gen-ID Lab Services Inc. (formerly known as Pacific Sunset Investments Inc.) since May 17, 2005. He serves as Director of Advanomics Corporation. Dr. Slilaty is one of the pioneers of Gene Therapy having developed the first gene delivery system applicable to humans in 1983. Dr. Slilaty's other distinguished scientific career accomplishments was the discovery of a new class of enzymes, the S24 Family of Proteases. Dr. Slilaty's other career accomplishments include elucidation of the molecular mechanism for cleavage of LexA, the repressor protein of the E. coli DNA repair system; developing the first site-directed mutagenesis system applicable directly to double-stranded DNA; cloning the gene for the first yeast-lytic enzyme (lytic B-1,3-glucanase); developing a new molecular strategy for increasing the rate of enzyme reactions; inventing the TrueBlue(R) Technology, a powerful new cloning system for accelerating gene discovery and most recently, developing a new transcriptomics technology for generating entire RNA profiles. Most recently, Dr. Slilaty, in collaboration with Institut National des Sciences Appliquée (France), State University of New York at Binghamton (USA) and École Polytechnique, Université de Montréal (Canada), designed, patented and advanced the development the first and currently the only known anticancer compound (Adva-27a) capable of destroying multidrug resistant cancer cells. He serves as an Adjunct Professor at Universite du Quebec in the Department of Microbiology and Biotechnology. He is an accomplished scientist and a highly skilled business executive. He is cited worldwide and profiled in a variety of reference manuals. Dr. Slilaty is the author of eleven original research papers and four issued (5,071,743; 5,883,244; 6,127,171 and 6,500,619) and one pending (60/532,774) US patents. He has received research grants from the NIH and NSF. He is the recipient of the 1981 award from the University of Arizona Foundation for Meritorious Performance in Teaching. Dr. Slilaty and his vast knowledge of the human genome equips Pacific Sunset with an innovative chairman that can advise Pacific Sunset Investments Inc.'s officers, directors and employees on testing procedures of DNA samples, help better analyze results of the SNPs (SNiPs) studies and provide overall support to insure the successful implementation of Gen ID's business plan. Dr. Slilaty received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University in 1976 and his Ph.D. in Molecular Biology from the University of Arizona in 1983.
Positions
- Company NameSunshine Biopharma, Inc.Stock CodeSBFMPositionChairman, President & CEORelated Securities
